B‐cell haematological malignancies and SARS‐CoV‐2 infection: Could immunological interventions influence the outcome?
Abstract B cell haematological malignancies (HMs) have been described as the worst cancer type for concomitant COVID‐19 in terms of mortality, with rates up to 65%. This risk factor for COVID‐19 cannot only be explained by comorbidities and advanced age of patients, but aggravated by secondary immun...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | eJHaem |
| Online Access: | https://doi.org/10.1002/jha2.249 |